J&J Consumer Business Picks Up, But Analysts See Long Road
This article was originally published in The Rose Sheet
Executive Summary
J&J’s consumer business inched up 1% operationally in Q3, including about 6% growth at constant currency in OTC/nutritionals. However, costs associated with the remediation of McNeil OTC facilities are expected to weigh on J&J through most of 2013.
You may also be interested in...
J&J On Product Reformulation: Consumer Demand Plays A Role
In an interview with “The Rose Sheet,” Johnson & Johnson’s Susan Nettesheim, vice president of toxicology and product stewardship, discussed the firm’s recent decision to reformulate its personal-care products without or with reduced levels of formaldehyde, phthalates, triclosan and other ingredients.
J&J’s Gorsky Promises Prioritization Of OTC Business
Johnson & Johnson’s Q2 was another quarter of flat consumer products growth, with the return of some OTCs to market delayed until 2013. In his quarterly earnings call debut, CEO Alex Gorsky emphasized the firm’s commitment to diversification and restoring the supply of OTC products.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.